Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Usha R. Pendurthi"'
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Abstract Crohn’s disease and ulcerative colitis are the two forms of disorders of the human inflammatory bowel disease with unknown etiologies. Endothelial cell protein C receptor (EPCR) is a multifunctional and multiligand receptor, which is expre
Externí odkaz:
https://doaj.org/article/85c508b614b942408bc8046a59867658
Publikováno v:
Blood Advances, Vol 1, Iss 25, Pp 2399-2413 (2017)
Abstract: Many pathophysiologic agents transform cryptic tissue factor (TF) on cells to prothrombotic TF, and one such stimulus is 4-hydroxy-2-nonenal (HNE), the most abundant aldehyde produced by the oxidation of ω-6 polyunsaturated fatty acids. HN
Externí odkaz:
https://doaj.org/article/27b055a35a3246809b0724192dbb2698
Autor:
Shiva Keshava, Jagan Sundaram, Anuradha Rajulapati, Charles T. Esmon, Usha R. Pendurthi, L. Vijaya Mohan Rao
Publikováno v:
Blood Advances, Vol 1, Iss 15, Pp 1206-1214 (2017)
Abstract: Recent studies established that clotting factor VIIa (FVIIa) binds endothelial cell protein C receptor (EPCR). It has been speculated that FVIIa interaction with EPCR might augment the hemostatic effect of recombinant FVIIa (rFVIIa) in ther
Externí odkaz:
https://doaj.org/article/414c43275e3f4e399e2a807b14913bcc
Publikováno v:
Blood Advances, Vol 1, Iss 13, Pp 849-862 (2017)
Abstract: A majority of tissue factor (TF) on cell surfaces exists in an encrypted state with minimal to no procoagulant activity. At present, it is unclear whether limited availability of phosphatidylserine (PS) and/or a specific membrane lipid in t
Externí odkaz:
https://doaj.org/article/3bce09633bc04ba798de34219ccd000b
Autor:
Vijay Kondreddy, Shiva Keshava, Kaushik Das, Jhansi Magisetty, L. Vijaya Mohan Rao, Usha R. Pendurthi
Publikováno v:
Blood. 140:1549-1564
Deep vein thrombosis (DVT) is the third most common cause of cardiovascular mortality. Several studies suggest that DVT occurs at the intersection of dysregulated inflammation and coagulation upon activation of inflammasome and secretion of interleuk
Autor:
Usha R. Pendurthi, L. Vijaya Mohan Rao, Steven Idell, Torry A. Tucker, Sanghamitra Sahoo, Shiva Keshava
The procoagulant protein tissue factor (F3) is a powerful growth promoter in many tumors, but its mechanism of action is not well understood. More generally, it is unknown whether hemostatic factors expressed on tumor cells influence tissue factor-me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254e9d0b4af1fc3d0e2e2f0d485d4388
https://doi.org/10.1158/0008-5472.c.6504674
https://doi.org/10.1158/0008-5472.c.6504674
Autor:
Usha R. Pendurthi, L. Vijaya Mohan Rao, Steven Idell, Torry A. Tucker, Sanghamitra Sahoo, Shiva Keshava
Supplementary File PDF 277K, Supplementary Methods: Includes additional details of reagents and methodology, and references. Supplementary Figure 1: Effect of FVIIa and thrombin on cell proliferation of wild-type REN, TF- or PAR1- knocked-down REN MP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57cb6172e32bab062ce05115f6568b43
https://doi.org/10.1158/0008-5472.22396844.v1
https://doi.org/10.1158/0008-5472.22396844.v1
Publikováno v:
Blood. 139:118-133
Coagulation protease, factor VIIa (FVIIa), binds to endothelial cell protein C receptor (EPCR) and induces anti-inflammatory and endothelial barrier protective responses via protease-activated receptor-1 (PAR1)–mediated, biased signaling. Our recen
Autor:
Jue Wang, Shiva Keshava, Kaushik Das, Richard Kolesnick, Xian-Cheng Jiang, Usha R. Pendurthi, L. Vijaya Mohan Rao
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 43(1)
Background: Our recent studies suggest that sphingomyelin levels in the plasma membrane influence TF (tissue factor) procoagulant activity. The current study was performed to investigate how alterations to sphingomyelin metabolic pathway would affect
Autor:
Charles T. Esmon, Usha R. Pendurthi, L. Vijaya Mohan Rao, Vijay Kondreddy, Shabbir A. Ansari, Kaushik Das, Shiva Keshava, John H. Griffin
Publikováno v:
Blood. 137:3428-3442
Recombinant factor FVIIa (rFVIIa) is used as a hemostatic agent to treat bleeding disorders in hemophilia patients with inhibitors and other groups of patients. Our recent studies showed that FVIIa binds endothelial cell protein C receptor (EPCR) and